» Articles » PMID: 22659219

Phosphoprotein Abundance Changes in Hypertensive Cardiac Remodeling

Overview
Journal J Proteomics
Publisher Elsevier
Specialty Biochemistry
Date 2012 Jun 5
PMID 22659219
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

There is over-whelming evidence that protein phosphorylations regulate cardiac function and remodeling. A wide variety of protein kinases, e.g., phosphoinositide 3-kinase (PI3K), Akt, GSK-3, TGFβ, and PKA, MAPKs, PKC, Erks, and Jaks, as well as phosphatases, e.g., phosphatase I (PP1) and calcineurin, control cardiomyocyte growth and contractility. In the present work, we used global phosphoprotein profiling to identify phosphorylated proteins associated with pressure overload (PO) cardiac hypertrophy and heart failure. Phosphoproteins from hypertrophic and systolic failing hearts from male hypertensive Dahl salt-sensitive rats, trans-aortic banded (TAC), and spontaneously hypertensive heart failure (SHHF) rats were analyzed. Profiling was performed by 2-dimensional difference in gel electrophoresis (2D-DIGE) on phospho-enriched proteins. A total of 25 common phosphoproteins with differences in abundance in (1) the 3 hypertrophic and/or (2) the 2 systolic failure heart models were identified (CI>99%) by matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) and Mascot analysis. Among these were (1) myofilament proteins, including alpha-tropomyosin and myosin regulatory light chain 2, cap Z interacting protein (cap ZIP), and tubulin β5; (2) mitochondrial proteins, including pyruvate dehydrogenase α, branch chain ketoacid dehydrogenase E1, and mitochondrial creatine kinase; (3) phosphatases, including protein phosphatase 2A and protein phosphatase 1 regulatory subunit; and (4) other proteins including proteosome subunits α type 3 and β type 7, and eukaryotic translation initiation factor 1A (eIF1A). The results include previously described and novel phosphoproteins in cardiac hypertrophy and systolic failure.

Citing Articles

Proteomics and Its Current Application in Biomedical Area: Concise Review.

Gobena S, Admassu B, Kinde M, Gessese A ScientificWorldJournal. 2024; 2024:4454744.

PMID: 38404932 PMC: 10894052. DOI: 10.1155/2024/4454744.


Proteomics of the heart.

Karpov O, Stotland A, Raedschelders K, Chazarin B, Ai L, Murray C Physiol Rev. 2024; 104(3):931-982.

PMID: 38300522 PMC: 11381016. DOI: 10.1152/physrev.00026.2023.


Phosphodiesterase in heart and vessels: from physiology to diseases.

Fu Q, Wang Y, Yan C, Xiang Y Physiol Rev. 2023; 104(2):765-834.

PMID: 37971403 PMC: 11281825. DOI: 10.1152/physrev.00015.2023.


Thin filament regulation of cardiac muscle power output: Implications for targets to improve human failing hearts.

Hanft L, Robinett J, Kalogeris T, Campbell K, Biesiadecki B, McDonald K J Gen Physiol. 2023; 155(5).

PMID: 37000170 PMC: 10067705. DOI: 10.1085/jgp.202213290.


Phosphoprotein Detection in Sweat Realized by Intercalation Structure 2D@3D g-CN@FeO Wearable Sensitive Motif.

Qiao Y, Qiao L, Zhao P, Zhang P, Wu F, Zhang J Biosensors (Basel). 2022; 12(6).

PMID: 35735509 PMC: 9220892. DOI: 10.3390/bios12060361.


References
1.
Muslin A . Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med. 2005; 15(6):225-9. DOI: 10.1016/j.tcm.2005.06.008. View

2.
Beckles D, Mascareno E, Siddiqui M . Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol. 2006; 45(6):350-7. DOI: 10.1016/j.vph.2006.05.006. View

3.
Takahashi T, Tang T, Lai N, Roth D, Rebolledo B, Saito M . Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation. 2006; 114(5):388-96. DOI: 10.1161/CIRCULATIONAHA.106.632513. View

4.
Lemke L, Bloem L, Fouts R, Esterman M, Sandusky G, Vlahos C . Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol. 2001; 33(8):1527-40. DOI: 10.1006/jmcc.2001.1415. View

5.
Liao Y, Zhao H, Ogai A, Kato H, Asakura M, Kim J . Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertens Res. 2008; 31(2):335-44. DOI: 10.1291/hypres.31.335. View